Company Filing History:
2 out of 1,829 
2 out of 2,405 
1 out of 250 
Years Active: 2009-2025
Title: Alissa A. Chackerian: Innovator in Anti-Cancer Therapies
Introduction
Alissa A. Chackerian is a prominent inventor based in Sunnyvale, CA (US). She has made significant contributions to the field of cancer research, particularly in the development of combination therapies that target critical pathways in cancer treatment. With a total of 5 patents to her name, her work has the potential to impact the lives of many patients battling cancer.
Latest Patents
Chackerian's latest patents include innovative approaches to anti-cancer combination therapies. One notable patent focuses on therapies comprising CTLA-4 and PD-1 blocking agents. This patent discloses combination therapies where the CTLA-4 blocking agent is an effector-silent anti-CTLA-4 antibody or fragment, paired with a PD-1 or PD-L1 antibody or fragment. Another significant patent outlines methods for determining differences in alpha-4 integrin activity by correlating changes in soluble vascular cell adhesion molecule (sVCAM) and/or soluble mucosal addressin cell adhesion molecule (sMAdCAM) levels. This method can be instrumental in evaluating the pharmacokinetics and pharmacodynamics of alpha-4 integrin inhibitors used to treat diseases associated with chronic inflammation.
Career Highlights
Throughout her career, Alissa has worked with notable companies in the pharmaceutical industry, including Schering Corporation and Merck Sharp & Dohme Corporation. Her experience in these organizations has allowed her to develop and refine her innovative ideas in cancer therapies.
Collaborations
Chackerian has collaborated with esteemed colleagues such as Robert A. Kastelein and Manfred Kopf. These partnerships have further enriched her research and contributed to the advancement of her patented technologies.
Conclusion
Alissa A. Chackerian stands out as a dedicated inventor in the field of cancer research. Her innovative patents and collaborations reflect her commitment to improving cancer treatment options. Her work continues to inspire advancements in medical science and offers hope for patients worldwide.